ICP
BIO icon

Ilex Capital Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ilex Capital Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,558
Closed -$28.2M – 80
2025
Q3 		$28.2M Sell
100,558
-20,327
-17% -$5.53M 0.9% 36
2025
Q2 		$29.2M Buy
120,885
+114,490
+1,790% +$27.1M 0.97% 33
2025
Q1 		$1.56M Buy
+6,395
New +$1.92M 0.06% 144

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ilex Capital Partners's BIO Position: Q4 2025 in Review

Ilex Capital Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2025, closing a stake of 100,558 shares — an estimated $28.2M sold.

Ilex Capital Partners first reported a position in BIO in Q1 2025 and held it in 3 quarters. The position peaked at $29.2M in Q2 2025. 398 funds tracked by Wall St. Rank hold BIO as of Q4 2025.

  • Ilex Capital Partners reported no remaining Bio-Rad Laboratories Class A position as of Q4 2025 after selling out during the quarter.
  • Ilex Capital Partners sold 100,558 Bio-Rad Laboratories Class A shares in Q4 2025, an estimated $28.2M.
  • Ilex Capital Partners first reported a position in Bio-Rad Laboratories Class A in Q1 2025 and held it in 3 quarters.
  • Ilex Capital Partners's Bio-Rad Laboratories Class A position peaked at $29.2M in Q2 2025.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2025.

Based on Ilex Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.